Navigation Links
CryoLife Announces First Clinical Use of BioFoam(R)
Date:9/10/2009

gical options for the control of intraoperative bleeding," said Steven G. Anderson, CryoLife president and chief executive officer. "We believe the unique adherence and expansion characteristics of this product make it useful for organ sealing and other future surgical applications. It is a wonderful complement to our existing hemostasis products, BioGlue(R) and HemoStase(TM)."

In December 2008, CryoLife received conditional approval from the FDA to conduct the feasibility phase of the company's BioFoam IDE submission for liver parenchymal sealing. The feasibility phase will enroll a total of 20 subjects at two investigational sites in the U.S. Before beginning this phase, the Company must receive final approval of the study protocol and related documents from the FDA and an additional approval of the study from the U.S. Department of Defense. CryoLife is in the final stages of this approval process and expects to start enrollment in Q4 2009.

During the European Association of Cardio-Thoracic Surgery (EACTS) annual meeting in Vienna, Austria Oct. 17-21, booth 43, CryoLife will be soliciting input from the attendees on potential future clinical applications for the use of BioFoam in cardiothoracic surgery.

About BioFoam

BioFoam, a protein hydrogel biomaterial developed by CryoLife, contains an expansion agent which generates a mixed-cell foam. The foam creates a mechanical barrier to decrease blood flow and pores for the blood to enter, leading to cellular aggregation and enhanced hemostasis. It is easily applied and can be used intraoperatively to control internal organ hemorrhage, limit blood loss, and reduce the need for future reoperations in liver resections. BioFoam is based on the same protein hydrogel technology platform from which BioGlue Surgical Adhesive was developed. BioFoam received C
'/>"/>

SOURCE CryoLife, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. CryoLifes Second Annual Surgical Congress for the Ross Procedure to Draw More than 130 Cardiovascular Surgeons from Around the World
2. CryoLife Announces Implants of First FDA-Cleared SynerGraft(R) Processed Human Cardiac Patch Material
3. CryoLife Receives FDA 510(k) Clearance for SynerGraft(R) Processed Human Cardiac Patch Material
4. CryoLife Reports Record First Quarter Revenues of $26.7 Million
5. CryoLife Announces Release Date and Teleconference Call Details for 2009 First Quarter Financial Results
6. CryoLife to Present at Sidotis 13th Annual New York Emerging Growth Institutional Forum
7. CryoLife Reports Record Annual Revenues of $105.1 Million for FY 2008
8. CryoLife Announces Release Date and Teleconference Call Details for 2008 Fourth Quarter and Year End Financial Results
9. CryoLife, Inc. Receives Tissue From 100,000th Donor, Marking Industry Milestone
10. CryoLife to Present at 20th Annual Piper Jaffray Health Care Conference
11. CryoLifes Fully Diluted Earnings Per Share Increased 71 Percent to $0.12 in Third quarter of 2008 from $0.07 in Third quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/29/2014)... 2014 Each year in the ... medical attention. In the military, burn injury is ... battlefield medical care. More than 800 service members ... wounds heal slowly, remain inflamed and often become ... debilitating and functionally damaging. While developments in supportive ...
(Date:9/29/2014)... start of the military conflicts in Iraq and Afghanistan, ... States with traumatic brain injury caused by exposure to ... explosive devices, or IEDs. Symptoms of traumatic brain injury ... and nausea, to more severe impairments in memory and ... Defense has recognized the critical importance and complexity of ...
(Date:9/29/2014)... Research and Markets  has announced the ... & Services, End-User , Application - Global Forecast to ... The global oligonucleotide synthesis market is expected to reach ... growing at a CAGR of 9.8% from 2014 to ... the basis of products and services, applications, end users, ...
(Date:9/29/2014)... diseases and biodiversity loss requires evolutionary thinking, argues ... Express that was co-authored by Bruce Tabashnik ... and Life Sciences. , For the first time, ... progress in addressing a broad set of challenges ... that consider evolutionary histories and the likelihood of ...
Breaking Biology Technology:Faster Healing with Fewer Scars 2Modeling shockwaves through the brain 2Modeling shockwaves through the brain 3Modeling shockwaves through the brain 4Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 2Oligonucleotide Synthesis (Diagnostics, PCR, QPCR, Gene Synthesis, NGS, DNA, RNAi) Market - Global Forecast to 2019 3Evolutionary biology: It's not just for textbooks anymore 2Evolutionary biology: It's not just for textbooks anymore 3
... Food Safety Authority (EFSA) concludes no safety concerns for ... response to Nutrition 21,s Application to market Chromax(R) chromium ... PURCHASE, N.Y., June 30 Nutrition 21, Inc. (Nasdaq: ... nutritional supplements under the Iceland Health(R) and Diabetes Essentials ...
... SEATTLE, June 30 Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: ... 3000(R), Russell 2000(R) and Russell Global(R) Indexes posted by Russell Investments ... Russell Investments reconstitutes its family of U.S. and global equity indexes ... of Russell,s U.S. indexes captures the 4,000 largest U.S. stocks as ...
... , FRANKLIN LAKES, N.J., June 29 BD (Becton, ... it will conduct a live webcast of its third fiscal quarter ... a.m. (EDT). BD will issue a press release detailing the ... the conference call, along with related slides, will be accessible through ...
Cached Biology Technology:EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 2EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 3EFSA Issues Positive Safety Statement for the Use of Chromium Picolinate in EU Food Supplements 4Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 2Cell Therapeutics Added to Russell 3000(R), Russell 2000(R) and Russell Global(R) Indexes 3
(Date:9/29/2014)... found that a combination of a real-time feedback system ... of residence resulted in a reduction of 37% in ... were 1360.49 kWh, which is equivalent to a reduction ... weeks. , In contrast, another eight halls, exposed ... alert, resulted in saw a 3.5% reduction in energy ...
(Date:9/29/2014)... dabrafenib has significant anti-tumour activity in patients with ... whose disease has progressed after chemotherapy, according to ... Congress in Madrid, Spain. , "Reports of ... considerable interest because these mutations may be associated ... says lead author Dr David Planchard, pulmonary oncologist ...
(Date:9/29/2014)... DNA from the skeleton of a man who lived 2,330 ... about ourselves as humans? A great deal when his DNA ... genetic terms found to-date in a region where modern ... , The man,s maternal DNA, or ,mitochondrial DNA, was ... evolution. Mitochondrial DNA provided the first evidence that we all ...
Breaking Biology News(10 mins):Promising results shown with targeted approaches in subsets of non-small cell lung cancer 2Promising results shown with targeted approaches in subsets of non-small cell lung cancer 3Ancient human genome from southern Africa throws light on our origins 2Ancient human genome from southern Africa throws light on our origins 3
... Comfortable living is not why so many different life ... the planet. , Writing this week in the Proceedings ... temperatures near the equator speed up the metabolisms of ... the creation of new species. , The finding - ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
... remember learning to swim? Thrashing around, floundering, until suddenly ... strokes of doggy-paddle propel you away from your parent's ... expert swimmers. Actually, fish larvae are pretty feeble when ... 'burst-and-coast'. Dr Ulrike Müller from Wageningen University studies how ...
Cached Biology News:Taking evolution's temperature: Researchers pinpoint the energy it takes to make a species 2Taking evolution's temperature: Researchers pinpoint the energy it takes to make a species 3Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3Even fish don't swim well when they're young! 2
...
Contains L-glutamine....
... Resolution - Efficiently separates ... to 1000 bp. It ... PCR fragments, small DNA ... enzyme digestion, and double-stranded ...
...
Biology Products: